Cargando…
Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes
Background. This prospective observational study aimed to verify the efficacy of erythropoietin zeta in the treatment of patients with low-risk myelodysplastic syndrome. Methods. Patients with low/int-1 IPSS risk and serum erythropoietin level below 500 U/L were enrolled. Treatment consisted of eryt...
Autores principales: | Vetro, Calogero, Di Giacomo, Valeria, Mannina, Donato, Magrin, Silvana, Mulè, Antonio, Mitra, Maria Enza, Siragusa, Sergio, Duminuco, Andrea, Garibaldi, Bruno, Vadalà, Maria Cristina Emanuela, Di Raimondo, Francesco, Palumbo, Giuseppe A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951463/ https://www.ncbi.nlm.nih.gov/pubmed/35329991 http://dx.doi.org/10.3390/jcm11061665 |
Ejemplares similares
-
Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting
por: Duminuco, Andrea, et al.
Publicado: (2022) -
Therapeutic innovation for multi-resistant candidemics: Synergy of isavuconazole and caspofungin association
por: Duminuco, Andrea, et al.
Publicado: (2021) -
Genetic variants of erythropoietin (EPO) and EPO receptor genes in familial erythrocytosis
por: Vočanec, Danijela, et al.
Publicado: (2018) -
Erythropoietin (EPO) in acute kidney injury
por: Moore, Elizabeth, et al.
Publicado: (2011) -
Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study
por: Trincavelli, Maria Letizia, et al.
Publicado: (2013)